Home › Core › ISCC-IDs › 28CrW83aVzFTC

View ISCC-ID

Core Data

28CrW83aVzFTC
ISCC-ID - digital asset identifier
CCjcYw5RM2y9k-CTPLE9jRPuu9P-CDi8vQzevUUky-CRmbLU25FXoXa
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

new tumour necrosis factor inhibitors for rheumatoid arthritis are there benefits from extending choice

Ledger Reference

coblo
Source Ledger/Blockchain
117554
N-th ISCC Decleration on source ledger
4c5d69a9a5faf6b83c4b41f11bbf238aa0a4ecbe24b68083f9818d1edbcff4e6
Hash of block that includes the ISCC-DECLARATION
98f890ec82375567593c410eb473df3eef722465a125af29e93c46aac9c8f9e2
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "D. L Scott", "@type": "Person"}, {"name": "A. Cope", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://ard.bmj.com/content/68/6/767.full.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "BMJ", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1136/ard.2008.105940", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCjcYw5RM2y9k-CTPLE9jRPuu9P-CDi8vQzevUUky-CRmbLU25FXoXa", "propertyID": "ISCC"}], "datePublished": "2009-05-12"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close